Neurogene Short Term Investments vs Current Deferred Revenue Analysis

NGNE Stock   22.36  0.28  1.24%   
Neurogene financial indicator trend analysis is infinitely more than just investigating Neurogene recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Neurogene is a good investment. Please check the relationship between Neurogene Short Term Investments and its Current Deferred Revenue accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurogene. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For information on how to trade Neurogene Stock refer to our How to Trade Neurogene Stock guide.

Short Term Investments vs Current Deferred Revenue

Short Term Investments vs Current Deferred Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Neurogene Short Term Investments account and Current Deferred Revenue. At this time, the significance of the direction appears to have no relationship.
The correlation between Neurogene's Short Term Investments and Current Deferred Revenue is 0.01. Overlapping area represents the amount of variation of Short Term Investments that can explain the historical movement of Current Deferred Revenue in the same time period over historical financial statements of Neurogene, assuming nothing else is changed. The correlation between historical values of Neurogene's Short Term Investments and Current Deferred Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Short Term Investments of Neurogene are associated (or correlated) with its Current Deferred Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Current Deferred Revenue has no effect on the direction of Short Term Investments i.e., Neurogene's Short Term Investments and Current Deferred Revenue go up and down completely randomly.

Correlation Coefficient

0.01
Relationship DirectionPositive 
Relationship StrengthInsignificant

Short Term Investments

Short Term Investments is an item under the current assets section of Neurogene balance sheet. It contains any investments Neurogene undertook that will expire in less than one year. These accounts contain financial instruments such as stocks or bonds that Neurogene can easily liquidate in the marketplace.

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.
Most indicators from Neurogene's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Neurogene current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurogene. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For information on how to trade Neurogene Stock refer to our How to Trade Neurogene Stock guide.As of December 23, 2024, Selling General Administrative is expected to decline to about 10.4 M. In addition to that, Issuance Of Capital Stock is expected to decline to about 76.8 M
 2022 2023 2024 (projected)
Net Interest Income1.3M2.9M1.6M
Cost Of Revenue3.2M3.3M2.4M

Neurogene fundamental ratios Correlations

0.520.50.460.680.06-0.39-0.290.430.270.6-0.310.86-0.030.3-0.40.160.62-0.370.85-0.040.440.53-0.520.56-0.03
0.520.540.770.170.67-0.78-0.310.74-0.350.51-0.80.690.13-0.350.140.710.080.190.710.470.860.77-0.580.75-0.63
0.50.540.920.510.04-0.040.23-0.020.20.1-0.780.39-0.50.53-0.330.120.08-0.260.390.020.810.72-0.730.73-0.4
0.460.770.920.340.36-0.30.150.230.00.1-0.90.46-0.250.21-0.110.45-0.04-0.040.470.370.930.84-0.80.84-0.52
0.680.170.510.34-0.57-0.17-0.380.130.180.48-0.320.6-0.220.51-0.93-0.40.84-0.910.58-0.340.320.25-0.680.320.31
0.060.670.040.36-0.57-0.480.070.52-0.30.05-0.310.190.38-0.60.790.95-0.510.820.220.720.40.450.00.4-0.61
-0.39-0.78-0.04-0.3-0.17-0.480.79-0.980.68-0.740.48-0.75-0.350.69-0.05-0.51-0.38-0.07-0.76-0.32-0.52-0.450.34-0.440.38
-0.29-0.310.230.15-0.380.070.79-0.790.66-0.850.07-0.65-0.290.520.320.04-0.730.33-0.640.16-0.08-0.040.13-0.05-0.05
0.430.74-0.020.230.130.52-0.98-0.79-0.670.76-0.360.780.41-0.70.080.540.40.10.790.330.450.46-0.290.44-0.31
0.27-0.350.20.00.18-0.30.680.66-0.67-0.420.2-0.26-0.280.76-0.13-0.3-0.13-0.13-0.27-0.23-0.21-0.190.09-0.170.22
0.60.510.10.10.480.05-0.74-0.850.76-0.42-0.170.830.22-0.26-0.310.10.72-0.30.83-0.220.230.22-0.210.23-0.08
-0.31-0.8-0.78-0.9-0.32-0.310.480.07-0.360.2-0.17-0.410.280.030.09-0.340.020.03-0.42-0.29-0.95-0.730.72-0.710.65
0.860.690.390.460.60.19-0.75-0.650.78-0.260.83-0.410.11-0.1-0.360.30.71-0.321.00.060.550.62-0.570.64-0.14
-0.030.13-0.5-0.25-0.220.38-0.35-0.290.41-0.280.220.280.11-0.540.230.540.040.220.120.61-0.29-0.280.07-0.250.39
0.3-0.350.530.210.51-0.60.690.52-0.70.76-0.260.03-0.1-0.54-0.54-0.520.15-0.53-0.11-0.44-0.030.01-0.220.050.29
-0.40.14-0.33-0.11-0.930.79-0.050.320.08-0.13-0.310.09-0.360.23-0.540.61-0.811.0-0.330.44-0.08-0.040.56-0.12-0.53
0.160.710.120.45-0.40.95-0.510.040.54-0.30.1-0.340.30.54-0.520.61-0.360.650.320.850.440.49-0.210.46-0.41
0.620.080.08-0.040.84-0.51-0.38-0.730.4-0.130.720.020.710.040.15-0.81-0.36-0.820.69-0.390.050.1-0.40.160.44
-0.370.19-0.26-0.04-0.910.82-0.070.330.1-0.13-0.30.03-0.320.22-0.531.00.65-0.82-0.30.47-0.020.020.5-0.06-0.57
0.850.710.390.470.580.22-0.76-0.640.79-0.270.83-0.421.00.12-0.11-0.330.320.69-0.30.080.560.63-0.570.65-0.15
-0.040.470.020.37-0.340.72-0.320.160.33-0.23-0.22-0.290.060.61-0.440.440.85-0.390.470.080.320.31-0.330.32-0.11
0.440.860.810.930.320.4-0.52-0.080.45-0.210.23-0.950.55-0.29-0.03-0.080.440.05-0.020.560.320.9-0.770.89-0.65
0.530.770.720.840.250.45-0.45-0.040.46-0.190.22-0.730.62-0.280.01-0.040.490.10.020.630.310.9-0.710.99-0.54
-0.52-0.58-0.73-0.8-0.680.00.340.13-0.290.09-0.210.72-0.570.07-0.220.56-0.21-0.40.5-0.57-0.33-0.77-0.71-0.770.01
0.560.750.730.840.320.4-0.44-0.050.44-0.170.23-0.710.64-0.250.05-0.120.460.16-0.060.650.320.890.99-0.77-0.45
-0.03-0.63-0.4-0.520.31-0.610.38-0.05-0.310.22-0.080.65-0.140.390.29-0.53-0.410.44-0.57-0.15-0.11-0.65-0.540.01-0.45
Click cells to compare fundamentals

Neurogene Account Relationship Matchups

Neurogene fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets147.0M210.5M101.5M109.3M222.6M155.8M
Short Long Term Debt Total1.2M12.1M5.2M4.7M16.3M17.1M
Other Current Liab2.5M5.9M4.6M5.3M17.5M18.4M
Total Current Liabilities4.7M7.9M10.9M6.7M23.0M24.1M
Total Stockholder Equity141.7M191.2M(91.9M)(145.7M)186.0M195.3M
Property Plant And Equipment Net2.8M13.7M27.5M24.5M21.0M12.6M
Net Debt(141.9M)(180.4M)(65.3M)(77.3M)(132.0M)(138.6M)
Retained Earnings(299.5M)(332.8M)(95.6M)(150.8M)(187.2M)(196.5M)
Cash143.1M192.6M70.5M82.0M148.2M109.7M
Non Current Assets Total3.4M16.0M27.5M24.5M22.2M20.2M
Non Currrent Assets Other597.0K2.3M(878K)87K764K480.6K
Cash And Short Term Investments143.1M192.6M70.5M82.0M197.2M133.8M
Common Stock Shares Outstanding27.0M51.8M55.0M12.8M14.7M14.0M
Liabilities And Stockholders Equity147.0M210.5M101.5M109.3M222.6M155.8M
Non Current Liabilities Total593K11.4M182.5M248.4M13.6M12.9M
Other Current Assets503K2.0M3.4M1.7M2.6M1.6M
Other Stockholder Equity441.2M524.0M3.8M5.1M373.2M224.1M
Total Liab5.3M19.3M193.4M255.0M36.5M34.7M
Total Current Assets143.6M194.5M74.0M84.7M200.3M135.7M
Accounts Payable1.6M1.3M5.6M625K2.6M2.3M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Neurogene is a strong investment it is important to analyze Neurogene's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Neurogene's future performance. For an informed investment choice regarding Neurogene Stock, refer to the following important reports:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurogene. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For information on how to trade Neurogene Stock refer to our How to Trade Neurogene Stock guide.
You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurogene. If investors know Neurogene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurogene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.66)
Revenue Per Share
0.106
Return On Assets
(0.32)
Return On Equity
(0.41)
The market value of Neurogene is measured differently than its book value, which is the value of Neurogene that is recorded on the company's balance sheet. Investors also form their own opinion of Neurogene's value that differs from its market value or its book value, called intrinsic value, which is Neurogene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurogene's market value can be influenced by many factors that don't directly affect Neurogene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neurogene's value and its price as these two are different measures arrived at by different means. Investors typically determine if Neurogene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurogene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.